BSE:IOB 18 December 2025

March 22, 2026, 10:19 AM EDT. Abbott Laboratories (ABT) has experienced recent share price weakness, sparking a reassessment of its valuation. Trading at $105.46, the stock shows a 6.02% gain over 30 days but reflects mixed longer-term returns, with a 15.08% year-to-date rise against a modest 5-year total shareholder return of 5.34%. Simply Wall St's analysis estimates a fair value of $113.88, suggesting an approximate 36% intrinsic discount and potential undervaluation. Despite a P/E ratio of 28.3x above the US Medical Equipment industry average, Abbott's strong fundamentals, innovation focus, and diversified portfolio support its position as a growth stock with defensive traits. However, risks include regulatory challenges and margin pressure from costs and competition. Investors should balance these rewards and risks to inform their investment outlook on ABT.